Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 33 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2022, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 8, 1, 11, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Musculoskeletal Disorders, Respiratory, Cardiovascular and Oncology which include indications Obesity, Type 2 Diabetes, Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Diastolic Heart Failure, Fibrosis, Idiopathic Pulmonary Fibrosis, Liver Fibrosis, Neuroendocrine Cancer, Obstructive Sleep Apnea, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Metabolic Disorders.
Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 33 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2022, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 8, 1, 11, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Musculoskeletal Disorders, Respiratory, Cardiovascular and Oncology which include indications Obesity, Type 2 Diabetes, Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Diastolic Heart Failure, Fibrosis, Idiopathic Pulmonary Fibrosis, Liver Fibrosis, Neuroendocrine Cancer, Obstructive Sleep Apnea, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Metabolic Disorders.
Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
- The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope
Introduction
Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
3B Pharmaceuticals GmbH
Amgen Inc
Antag Therapeutics ApS
Bainan Biotech ApS
Carmot Therapeutics Inc
D&D Pharmatech Co Ltd
Eli Lilly and Co
Gmax Biopharm LLC
Great Bay Bio Holdings Ltd
Hanmi Pharmaceuticals Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Kariya Pharmaceuticals IVS
Longevity Biotech Inc
Novo Nordisk AS
Onegene Biotechnology Inc
Sciwind Biosciences Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Viking Therapeutics Inc
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
(semaglutide + GIP analogue) - Drug Profile
Product Description
Mechanism Of Action
History of Events
3B-401 - Drug Profile
Product Description
Mechanism Of Action
AMG-133 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CT-868 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DAJC-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DD-03 - Drug Profile
Product Description
Mechanism Of Action
DR-10624 - Drug Profile
Product Description
Mechanism Of Action
DR-10625 - Drug Profile
Product Description
Mechanism Of Action
DR-10627 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DR-10628 - Drug Profile
Product Description
Mechanism Of Action
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
GIPR AGONIST LA II - Drug Profile
Product Description
Mechanism Of Action
GMA-106 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HS-20094 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KP-405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LBT-6030 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3437943 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3493269 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3537021 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OGB-21501 - Drug Profile
Product Description
Mechanism Of Action
Peptides to Antagonize GIPR for Obesity - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Peptide to Activate GIPR for Type I Diabetes - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
THDBH-120 - Drug Profile
Product Description
Mechanism Of Action
THDBH-121 - Drug Profile
Product Description
Mechanism Of Action
tirzepatide - Drug Profile
Product Description
Mechanism Of Action
History of Events
VK-2735 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XW-003 + XW-017 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZP-6590 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
Featured News & Press Releases
Jul 07, 2022: Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist “Tirzepatide”
Jun 10, 2022: Lilly eyes weight loss arena for diabetes drug tirzepatide after positive data
Jun 08, 2022: Sciwind Biosciences to present data from its GLP-1 Program at The International Liver Congress EASL 2022
Jun 06, 2022: New analyses of Mounjaro (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's 82nd Scientific Sessions
Jun 04, 2022: SURMOUNT-1 Study Finds Individuals with Obesity Lost up to 22.5% of their Body Weight when Taking Tirzepatide
Jun 04, 2022: Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
Jun 03, 2022: Tirzepatide slowed progression of chronic kidney disease in patients with type 2 diabetes with increased cardiovascular risk
May 16, 2022: Lilly’s Mounjaro receives FDA approval for type 2 diabetes treatment
Apr 28, 2022: Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
Apr 26, 2022: AMRA Medical's MRI-based body composition measurements used in Lilly's SURPASS-3 tirzepatide sub-study
Apr 08, 2022: Announcement of Huadong Medicine on obtaining the approval notice of drug clinical trial for its holding subsidiary
Jan 10, 2022: Viking Therapeutics announces initiation of phase 1 clinical trial of VK2735, company's lead dual GLP-1/GIP receptor agonist
Nov 11, 2021: Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
Nov 01, 2021: Viking Therapeutics presents preclinical data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Oct 20, 2021: Lilly’s tirzepatide reduces body weight in Phase III type 2 diabetes trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
3B Pharmaceuticals GmbH
Amgen Inc
Antag Therapeutics ApS
Bainan Biotech ApS
Carmot Therapeutics Inc
D&D Pharmatech Co Ltd
Eli Lilly and Co
Gmax Biopharm LLC
Great Bay Bio Holdings Ltd
Hanmi Pharmaceuticals Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Kariya Pharmaceuticals IVS
Longevity Biotech Inc
Novo Nordisk AS
Onegene Biotechnology Inc
Sciwind Biosciences Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Viking Therapeutics Inc
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
(semaglutide + GIP analogue) - Drug Profile
Product Description
Mechanism Of Action
History of Events
3B-401 - Drug Profile
Product Description
Mechanism Of Action
AMG-133 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CT-868 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DAJC-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DD-03 - Drug Profile
Product Description
Mechanism Of Action
DR-10624 - Drug Profile
Product Description
Mechanism Of Action
DR-10625 - Drug Profile
Product Description
Mechanism Of Action
DR-10627 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DR-10628 - Drug Profile
Product Description
Mechanism Of Action
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
GIPR AGONIST LA II - Drug Profile
Product Description
Mechanism Of Action
GMA-106 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HS-20094 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KP-405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LBT-6030 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3437943 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3493269 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3537021 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OGB-21501 - Drug Profile
Product Description
Mechanism Of Action
Peptides to Antagonize GIPR for Obesity - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Peptide to Activate GIPR for Type I Diabetes - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
THDBH-120 - Drug Profile
Product Description
Mechanism Of Action
THDBH-121 - Drug Profile
Product Description
Mechanism Of Action
tirzepatide - Drug Profile
Product Description
Mechanism Of Action
History of Events
VK-2735 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XW-003 + XW-017 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZP-6590 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
Featured News & Press Releases
Jul 07, 2022: Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist “Tirzepatide”
Jun 10, 2022: Lilly eyes weight loss arena for diabetes drug tirzepatide after positive data
Jun 08, 2022: Sciwind Biosciences to present data from its GLP-1 Program at The International Liver Congress EASL 2022
Jun 06, 2022: New analyses of Mounjaro (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's 82nd Scientific Sessions
Jun 04, 2022: SURMOUNT-1 Study Finds Individuals with Obesity Lost up to 22.5% of their Body Weight when Taking Tirzepatide
Jun 04, 2022: Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
Jun 03, 2022: Tirzepatide slowed progression of chronic kidney disease in patients with type 2 diabetes with increased cardiovascular risk
May 16, 2022: Lilly’s Mounjaro receives FDA approval for type 2 diabetes treatment
Apr 28, 2022: Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
Apr 26, 2022: AMRA Medical's MRI-based body composition measurements used in Lilly's SURPASS-3 tirzepatide sub-study
Apr 08, 2022: Announcement of Huadong Medicine on obtaining the approval notice of drug clinical trial for its holding subsidiary
Jan 10, 2022: Viking Therapeutics announces initiation of phase 1 clinical trial of VK2735, company's lead dual GLP-1/GIP receptor agonist
Nov 11, 2021: Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
Nov 01, 2021: Viking Therapeutics presents preclinical data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Oct 20, 2021: Lilly’s tirzepatide reduces body weight in Phase III type 2 diabetes trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
